Pharmaceutical composition to prevent tissue damage due to arterial blood flow failure
CA 2789161 C · Owner: Centro De Ingenieria Genetica Y Biotecnologia · Inventors: Suarez Alba, Jose; Berlanga Acosta, Jorge; Martinez Rodriguez, Rebeca
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to human medicine and particularly to a pharmaceutical composition comprising Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP-6); being useful to prevent tissue damages due to blood flow suppression and to enhance tissue repair following ischaemic damage. Alternatively a subject may also receive both EGF and GHRP-6 separately but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This composition attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 17, 2001 and granted April 7, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 17, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 17, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.